Pharmaceuticals
Pharma - MNC bulk Drugs
from 4,711 today
Pfizer's Q1FY27 performance was in line with expectations, driven by steady revenue growth and margin expansion aided by cost rationalisation and strong traction in key brands. We maintain our BUY rating with an unchanged target price of INR 6,000.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
